SequelSEC

HARVARD BIOSCIENCE INC HBIO

Laboratory Analytical Instruments · CIK 0001123494 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$87.81M
Fiscal year ended 2026-06-30
Operating income
-$245.00K
Fiscal year ended 2026-06-30
Free cash flow
-$1.12M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$18.20MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.41Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Laboratory Analytical Instruments filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Long-term debt / equity2.61x100th
Revenue YoY growth-8.1%9th
CapEx / revenue1.5%16th
Gross margin57.7%79th
R&D / revenue10.2%26th
SBC / revenue2.1%30th
Net margin-65.5%36th
FCF margin6.3%61th
Current ratio2.20x39th
Operating margin-56.1%45th

HARVARD BIOSCIENCE INC (HBIO) reported revenue of $87.81M and net income of -$10.41M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from HARVARD BIOSCIENCE INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

HARVARD BIOSCIENCE INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$87.81M
Cost of revenue$36.74M
Gross profit$51.07M
Operating income-$245.00K
Net income-$10.41M
Research & development$9.09M
Weighted-average diluted sharesUnavailable
Pretax income-$10.54M
Income tax expense-$129.00K
Diluted EPSUnavailable
Selling, general & administrative$38.06M
General & administrative$17.61M
Selling & marketing$20.44M

Balance

HARVARD BIOSCIENCE INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$6.50M
Total assets$76.29M
Current assets$46.46M
Total liabilities$68.87M
Current liabilities$24.79M
Total equity incl. NCI$7.42M
Temporary (mezzanine) equityUnavailable
Inventory$22.23M
Accounts receivable$14.50M
Goodwill$9.33M
Long-term debt$36.68M
Accounts payable$6.22M

Cash flow

HARVARD BIOSCIENCE INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$651.00K
Capital expenditures$1.77M
Investing cash flow-$2.48M
Financing cash flow$1.12M
Net change in cash-$939.00K
Stock-based compensation$1.42M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

HARVARD BIOSCIENCE INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$1.12M
Gross margin58.2%
Operating margin-0.3%
FCF margin-1.3%
SBC / revenue1.6%
Current ratio1.87x
Revenue YoY growth-1.1%
Net margin-11.9%
R&D / revenue10.4%
CapEx / revenue2.0%
Long-term debt / equity4.94x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HBIO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

A ASTC AVTR BFNH BIO BNGO BRKR CTKB EYPT ILMN LCTC MASS

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.